scholarly journals Cost-effectiveness analysis of intraoperative radiation therapy versus external beam radiation therapy for the adjuvant treatment of early breast cancer: A systematic review

2020 ◽  
Author(s):  
Mahmoud Eisavi ◽  
Aziz Rezapour ◽  
Vahid Alipour ◽  
Hamid Reza Mirzaei ◽  
Jalal Arabloo
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Radiation Therapy ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
Intraoperative Radiation Therapy ◽  
External Beam ◽  
Beam Radiation ◽  
Intraoperative Radiation ◽  
Effectiveness Analysis

Preoperative Paclitaxel and Concurrent Rapid-Fractionation Radiation for Resectable Pancreatic Adenocarcinoma: Toxicities, Histologic Response Rates, and Event-Free Outcome

2002 ◽  
Vol 20 (10) ◽  
pp. 2537-2544 ◽  
Author(s):  
Peter W. T. Pisters ◽  
Robert A. Wolff ◽  
Nora A. Janjan ◽  
Karen R. Cleary ◽  
Chusilp Charnsangavej ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Pancreatic Adenocarcinoma ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
Intraoperative Radiation Therapy ◽  
Preoperative Treatment ◽  
External Beam ◽  
Beam Radiation ◽  
Intraoperative Radiation ◽  
Grade 3

PURPOSE: To evaluate the toxicity of a preoperative regimen of paclitaxel and concurrent external-beam radiation therapy, pancreaticoduodenectomy, and electron-beam intraoperative radiation therapy (EB-IORT) for patients with resectable pancreatic adenocarcinoma. PATIENTS AND METHODS: Patients with localized, potentially resectable pancreatic adenocarcinoma were treated with 30 Gy external-beam radiation therapy and concomitant weekly 3-hour infusions of paclitaxel (60 mg/m2). Radiographic restaging was performed 4 to 6 weeks after chemoradiation, and patients with localized disease underwent pancreatectomy with EB-IORT. RESULTS: Thirty-five patients completed chemoradiation; 16 (46%) experienced grade 3 toxicity. Four patients (11%) required hospitalization for dehydration due to grade 3 nausea and vomiting. Twenty (80%) of 25 patients who underwent surgery underwent pancreatectomy; EB-IORT was used in 13 patients. There were no histologic complete responses to preoperative therapy; 21% of specimens demonstrated more than 50% nonviable cells (grade 2b treatment effect). With a median follow-up period of 46 months, the 3-year overall survival rate with chemoradiation and pancreatectomy was 28%. CONCLUSION: Preoperative paclitaxel-based concurrent chemoradiation is feasible. The toxicity of this regimen seems greater than that with fluorouracil. The histologic responses and survival are similar, suggesting no advantages to paclitaxel-based preoperative treatment.

Sign in / Sign up

Export Citation Format

Share Document